Today: 29 April 2026
Browse Category

LSE:III.L 9 January 2026 - 17 February 2026

3i Group share price edges up as BoE rate-cut bets grow — what investors watch next

3i Group share price edges up as BoE rate-cut bets grow — what investors watch next

3i Group shares rose 0.3% to 3,507 pence by 0858 GMT Tuesday, after a 1.8% gain Monday. UK unemployment climbed to 5.2% in Q4 2025 and wage growth slowed, reviving bets on a Bank of England rate cut in March. 3i’s net asset value reached 3,017 pence at Dec. 31, with Action’s sales growth accelerating in early 2026. Investors await 3i’s Action Capital Markets Seminar on March 26.
17 February 2026
··
FTSE 100 rises as miners lift London stocks; 3i soars, Lloyds upgrades targets

FTSE 100 rises as miners lift London stocks; 3i soars, Lloyds upgrades targets

London’s FTSE 100 rose 0.44% to 10,198.75 by 1105 GMT, led by mining and financial stocks. Gold surged near $5,600 an ounce, hitting new highs as investors sought safe havens amid geopolitical tensions and a weaker dollar. 3i Group jumped 14% after strong results from Action, while Lloyds gained 0.5% on a profit beat and new share buyback. Sterling hovered near multi-year highs against the dollar.
29 January 2026
····
3i Group share price jumps as Action sales pick up; £1bn GIC deal in focus

3i Group share price jumps as Action sales pick up; £1bn GIC deal in focus

3i Group shares surged 10.6% after reporting stronger January trading at Action and announcing a deal to raise its stake in the retailer to 65.3% via a share-funded transaction with GIC. Diluted NAV per share rose to 3,017 pence as of Dec. 31. Action’s like-for-like sales grew 6.1% in January after a slower 2025, with France recovering from earlier declines. The GIC deal is expected to close Jan. 30.
29 January 2026
·
3i Group share price inches up as RBC’s Action warning hangs over stock

3i Group share price inches up as RBC’s Action warning hangs over stock

3i Group shares rose 0.35% to 3,146p Wednesday after a sharp 4.86% drop on Monday. RBC downgraded the stock to “Underperform,” citing risk of “diminishing returns” at key holding Action and cut its price target to 3,000p. Barclays trimmed its target but kept an “overweight” rating. Investors await Thursday’s trading update for details on Action and net asset value.
28 January 2026
·
3i Group stock slips again in London as Jan 29 update nears

3i Group stock slips again in London as Jan 29 update nears

3i Group shares fell 0.7% to 3,101 pence by 0942 GMT, extending recent losses as investors await the company’s Q3 update on Jan. 29. The stock trades at an 11% premium to net asset value but remains 31% below its 52-week high. European markets slipped after U.S. policy news hit banks and dampened risk appetite.
12 January 2026
·

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 2:57 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Go toTop